secwatch.observer — SEC 8-K summary
======================================

Issuer:     Caribou Biosciences, Inc. (CRBU)
CIK:        0001619856
Form:       8-K
Filed at:   2025-08-12T23:59:59+00:00
Accession:  0001619856-25-000060
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Caribou Q2 net loss $54.1M ($0.58/sh); clinical data on track for H2 2025
-------------------------------------------------------------------------

- GAAP net loss $54.1M ($0.58/sh) vs $37.7M ($0.42/sh) in Q2 2024; non-GAAP loss $32.8M ($0.35/sh) excluding $21.3M impairment.
- Cash $183.9M as of June 30, down from $249.4M at Dec 31; expected to fund operations into H2 2027.
- Completed enrollment of 20-patient confirmatory cohort for CB-010 in 2L LBCL; data and pivotal trial plans expected H2 2025.
- Completed dose escalation enrollment for CB-011 CaMMouflage trial in r/r MM; dose expansion data expected H2 2025.
- R&D expenses fell to $27.7M from $35.5M due to pipeline prioritization and workforce reduction; G&A down to $10.4M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1619856/000161985625000060/0001619856-25-000060-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1619856/000161985625000060/crbu-20250812.htm
  HTML page:      https://secwatch.observer/filing/0001619856-25-000060

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer